Highlights Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
39.82 ^USD	+1.32%		+3.54%	+7.74%

Apr. 25	Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	CI
Apr. 18	Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	Feb. 21	MT
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	Feb. 20	CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	Feb. 20	MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	Feb. 20	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	Feb. 20	MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	Feb. 20	MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20	CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	Feb. 20	CI
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20	CI
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	Jan. 31	CI
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 29	CI
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients	Jan. 18	MT
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis	Jan. 18	CI
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023	Jan. 17	CI
Halozyme Therapeutics Says Roche Gets European Commission's Approval for Tecentriq SC	Jan. 16	MT
Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 16	CI
Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types	Jan. 16	CI
Halozyme Says Argenx Obtains European Clearance of Vyvgart With Enhanze for Myasthenia Gravis	Nov. 16	MT
Halozyme Therapeutics' Q3 Non-GAAP Earnings, Revenue Rise; Full-Year 2023 Adjusted EPS Outlook Raised	Nov. 06	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q3 EPS $0.75, vs. Street Est of $0.71	Nov. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Highlights

Filters